Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" google.com

ASH 2025: Myelofibrosis Roundup

google.com·14w

Incyte weak 2026 revenue forecast heightens Jakafi patent concerns

google.com·14w

FDA Guidance Signals Shift Toward MRD-Driven Accelerated Approvals in Multiple Myeloma

google.com·14w

Galecto announces public offering of common and preferred stock

google.com·14w

Dual Antibodies Beat Single for Type 1 CALR-Mutant Myelofibrosis

google.com·14w

Incyte (INCY) Q4 2025 Earnings Call Transcript

google.com·14w

Active Biotech receives positive feedback on its clinical study with tasquinimod in myelofibrosis

google.com·14w

Active Biotech Wins Approval to Resume Expanded Tasquinimod Myelofibrosis Trial

google.com·14w

Global Study Marks Major Treatment Advance for Tough-to-Treat High-Risk Blood Cancer

google.com·14w

Dr Mascarenhas on CALR-Directed Agents and Investigational Targeted Therapies in MPNs

google.com·14w

In Intermediate-Risk Myelofibrosis , Experts Focus on Symptom Relief

google.com·14w

FDA Grants Orphan Drug Status to Zavabresib for Myelofibrosis Therapy

google.com·14w

FDA Clears Prelude's Experimental Cancer Drug, Opening New Path for Blood Disorders

google.com·14w

Takeda Advances Elritercept Study in Myelofibrosis , Keeping Anemia-Focused Pipeline in ...

google.com·14w

Myelofibrosis Clinical Trials Outlook: Competitive

google.com·14w

Takeda Advances Elritercept Study in Myelofibrosis , Keeping Anemia-Focused Pipeline ...

google.com·15w

Ultraprecision Targeting of CALR Mutations Signals a New Era in Myelofibrosis Treatment

google.com·15w

Preserving thrombosis and life years in polycythemia vera : start by reading the biology of the disease

google.com·15w

SNT: Positive Phase 2 amsulostat data and strong funding position drive near-term value

google.com·15w

Prelude's JAK2 V617F inhibitor PRT-12396 gains IND clearance

google.com·15w

Log in to enable infinite scrolling